SingleSexual & Hormonal

Oxytocin 5mg

Endogenous nonapeptide hormone and oxytocin-receptor agonist investigated for neuroendocrine signaling, bonding, and stress response.

Mechanism

Acts as a selective agonist at the oxytocin receptor (OXTR), a G-protein-coupled receptor that mediates peripheral smooth muscle contraction and modulates central neuroendocrine pathways involved in social affiliation and stress signaling.

Dosing

Standard experimental protocols document an initial daily dose of 100 mcg administered subcutaneously.

Reconstitution

Reconstituting a 5 mg vial with 3.0 mL of bacteriostatic water yields an approximate working concentration of 1.67 mg/mL (1,667 mcg/mL).

Storage

Store the unmixed lyophilized vial frozen at -20 °C, and once reconstituted, maintain refrigerated at 2–8 °C for up to 28 days without freezing.

Mix & measure Oxytocin 5mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Oxytocin 5mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration1.67mg/mL

Draw volume0.060mL

On the syringe6.00units

Total doses in vial: 50.0

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Weeks 1–2	100 mcg (1× daily)	6 units (0.06 mL)
Weeks 3–4	200 mcg (1× daily)	12 units (0.12 mL)
Weeks 5–6	300 mcg (1× daily)	18 units (0.18 mL)
Weeks 7–8	400 mcg (1× daily)	24 units (0.24 mL)
Weeks 9–12	500 mcg (1× daily)	30 units (0.30 mL)

Reconstitution Steps

1
Draw 3.0 mL of bacteriostatic water using a sterile syringe.
2
Gently inject the diluent along the interior glass wall of the 5 mg oxytocin vial to avoid turbulence and foaming.
3
Slowly roll or swirl the vial between your palms until the lyophilized powder fully dissolves; avoid shaking.
4
Record the date and resulting concentration (~1.67 mg/mL) on the vial label.
5
Place the reconstituted vial into refrigeration at 2–8 °C, ensuring it is kept protected from light.

Supplies Needed

Peptide Vial

Oxytocin 5 mg lyophilized powder

Insulin Syringes (U-100)

0.5 mL or 1 mL U-100 syringes for accurate micro-volume draws

Bacteriostatic Water

3.0 mL per vial for dilution

Alcohol Swabs

Antiseptic preparation of vial tops and administration sites

Why researchers study it

Social bonding & trust signaling pathways

Anxiety, social fear, & HPA-axis stress reactivity

Libido, arousal, & pair-bonding physiology

Smooth-muscle contractility & obstetric models

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Oxytocin is an endogenous cyclic nonapeptide produced within the hypothalamus and secreted primarily by the posterior pituitary. In conventional medicine, synthetic oxytocin is established as an intravenous or intramuscular agent indicated for obstetric applications such as labor induction and the management of postpartum hemorrhage. However, broader exploration into its neuromodulatory capacities has driven substantial interest across laboratory research settings. In preclinical and clinical investigative models, researchers evaluate oxytocin for its complex roles in central nervous system pathways, including prosocial behaviors, affiliative bonding, emotional regulation, and moderation of the hypothalamic-pituitary-adrenal (HPA) stress response. Outside of obstetric clinical practice, systemic and central administration protocols remain purely experimental, as pharmacokinetic barriers like rapid enzymatic degradation and limited blood-brain barrier permeability present distinct hurdles in translational settings. This protocol documentation provides standard reconstitution parameters, measurement guidelines, and experimental titration increments reported in contemporary literature for a 5 mg research vial. These details serve strictly as educational references for laboratory investigators exploring receptor kinetics, behavioral assays, and related biochemical endpoints.

References

1.StatPearls / NCBI Bookshelf, 2023 — Oxytocin: nonapeptide structure, OXTR signalling, and physiology of uterine contraction and lactation
2.Psychoneuroendocrinology, 2020 — Reviews of oxytocin as a social/bonding neuromodulator
3.Clinical Pharmacokinetics, 2018 — Oxytocin pharmacokinetics and short plasma half-life
4.Journal of Neuroendocrinology, 2019 — Dosing and bioavailability across routes of administration
5.Sikich et al., NEJM, 2021 — SOARS-B randomized trial of intranasal oxytocin in autistic children
6.FDA Label / CDER, 2021 — Prescribing information for Pitocin (oxytocin injection)
7.Frontiers in Neuroscience, 2020 — Oxytocin modulation of the HPA stress axis and dopaminergic circuits
8.Neuropsychopharmacology, 2016 — Blood-brain barrier penetration and intranasal delivery rationale
9.Systematic Review, 2021 — Intranasal oxytocin in anxiety and psychiatric conditions
10.Diabetes / Metabolism, 2015 — Acute intranasal oxytocin and caloric intake modulation in humans
11.Cochrane Database of Systematic Reviews, 2018 — Oxytocin for labor induction and postpartum hemorrhage prevention
12.Biological Psychiatry, 2016 — Oxytocin trials in psychiatric disorders and effect size replication
13.CDC, 2021 — Subcutaneous administration technique guidelines